Versartis Obtains $21,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8014cbf6-b7cd-47b5-ad14-53d1f99f3349&Preview=1 -
Date
2/16/2011 -
Company Name
Versartis -
Mailing Address
500 Ellis Street Mountain View, CA 94043 -
Company Description
Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix. -
Website
http://www.versartis.com -
Transaction Type
Venture Equity -
Transaction Amount
$21,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Versartis plans to use the proceeds primarily to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency (GHD) in both adult and pediatric patients. -
M&A Terms
-
Venture Investor
New Leaf Venture Partners -
Venture Investor
Advent Venture Partners -
Venture Investor
Index Ventures -
Venture Investor
Undisclosed
